6 citations
,
January 2019 in “Journal of dermatology” Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.
April 2023 in “American Journal of Transplantation” Hormone replacement therapy may lower the risk of severe COVID-19 outcomes in non-immunosuppressed people and male organ transplant recipients.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
20 citations
,
March 2019 in “Case Reports in Dermatology” IL-17 inhibitors for psoriasis may cause unexpected hair loss.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
October 2025 in “The American Journal of Gastroenterology” Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.
1 citations
,
October 2010 in “Faṣlnāmah-i bīmārīhā-yi pūst” Methotrexate with corticosteroids can help regrow hair in severe alopecia areata but may cause relapses and side effects.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
9 citations
,
January 2013 in “Indian journal of dermatology, venereology, and leprology” Infliximab may cause hair loss in Crohn's disease patients.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.